Middle Pancreatectomy for Low‐Grade Malignancies: Superior Long‐Term Glucose Tolerance Preservation Over Distal Pancreatectomy
Journal of Hepato-Biliary-Pancreatic Sciences · 2026
DOI: 10.1002/jhbp.70121 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Hepato-Biliary-Pancreatic Sciences, 2026. Verfasst von Atsuro Fujinaga und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Pancreatectomy, Pancreatic Neoplasms, Blood Glucose. Die Arbeit nennt 31 Literaturangaben. Gefördert von: National Cancer Center Research and Development Fund.
Abstract (Originalsprache)
Background
This study compared outcomes of middle pancreatectomy (MP) and distal pancreatectomy (DP), focusing on long‐term glucose tolerance.
Methods
We retrospectively reviewed 282 patients who underwent MP ( n = 69) or DP ( n = 213) for low‐grade malignant tumors from 2000 to 2020. Surgical outcomes, HbA1c levels, prevalence of diabetes mellitus (DM), and escalation of antidiabetic medication were analyzed.
Results
MP was associated with longer operation time (312 vs. 245 min, p < 0.001) and higher pancreatic fistula rate (64% vs. 47%, p = 0.018). Among 248 patients with 3‐year follow‐up, MP showed lower HbA1c levels (5.9% vs. 6.3%, p < 0.001), lower incidence of new‐onset DM (3% vs. 30%, p < 0.001), and fewer cases of increased antidiabetic medication use (8% vs. 24%, p = 0.005). Insulin therapy was newly required in 1 MP case versus 18 DP cases.
Conclusion
Despite higher morbidity, MP demonstrated superior preservation of long‐term glucose tolerance compared with DP. These findings suggest that MP is a valuable parenchyma‐preserving option for patients with low‐grade malignant pancreatic tumors, particularly those at increased risk of postoperative DM, although careful consideration of surgical risks is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, Tokyo, Japan.
ORCID-Profile: Atsuro Fujinaga
Förderung
- National Cancer Center Research and Development Fund
Zitieren
APA
Fujinaga, A., Esaki, M., Kitamura, K., Umino, R., Mizui, T., Miyata, A., & Nara, S. (2026). Middle Pancreatectomy for Low‐Grade Malignancies: Superior Long‐Term Glucose Tolerance Preservation Over Distal Pancreatectomy. Journal of Hepato-Biliary-Pancreatic Sciences. https://doi.org/10.1002/jhbp.70121
Vancouver
Fujinaga A, Esaki M, Kitamura K, Umino R, Mizui T, Miyata A, et al. Middle Pancreatectomy for Low‐Grade Malignancies: Superior Long‐Term Glucose Tolerance Preservation Over Distal Pancreatectomy. Journal of Hepato-Biliary-Pancreatic Sciences. 2026. doi:10.1002/jhbp.70121
BibTeX
@article{Fujinaga2026,
author = {Fujinaga, Atsuro and Esaki, Minoru and Kitamura, Kei and Umino, Ryosuke and Mizui, Takahiro and Miyata, Akinori and Nara, Satoshi},
title = {Middle Pancreatectomy for Low‐Grade Malignancies: Superior Long‐Term Glucose Tolerance Preservation Over Distal Pancreatectomy},
journal = {Journal of Hepato-Biliary-Pancreatic Sciences},
year = {2026},
doi = {10.1002/jhbp.70121}
}
EUVIMED